Home-based administration of Sayana® Press: review and assessment of needs in low-resource settings

Contraception. 2014 May;89(5):344-51. doi: 10.1016/j.contraception.2014.03.003. Epub 2014 Mar 12.


A new presentation of the subcutaneous (SC) injectable contraceptive depot medroxyprogesterone acetate (DMPA) increases the possibilities for home and self-administration of this popular contraceptive method. Sayana® Press is DMPA-SC in the prefilled Uniject™ injection system and consists of one dose that provides 3 months of contraceptive protection. Studies indicate that lay caregiver and self-injection of various medications, including other injectable presentations of DMPA-SC, are acceptable and effective. Introduction of Sayana® Press in developing countries could extend injectable contraceptive delivery safely and effectively beyond the clinic and, eventually, into the home, allowing lay caregiver or self-administration. Research needs for low-resource settings include assessing the acceptability and feasibility of self-injection with Sayana® Press. Feasibility studies necessary for implementing a sustainable home-based delivery program include assessment of training, health systems, policies, infrastructure needs and programmatic considerations to optimize women's ability to manage their self-injection schedule.

Keywords: Acceptability; Family planning; Feasibility; Injectable contraceptive; Sayana Press; Self-injection.

Publication types

  • Review

MeSH terms

  • Contraceptive Agents, Female / administration & dosage*
  • Developing Countries*
  • Female
  • Home Care Services*
  • Humans
  • Injections, Subcutaneous
  • Medroxyprogesterone Acetate / administration & dosage*
  • Needs Assessment
  • Self Administration


  • Contraceptive Agents, Female
  • Medroxyprogesterone Acetate